Thrombosis

Cryoablation Safety Profiled In Animal Models

Published in Blood Weekly, December 13th, 2001

Two leading cardiology research centers presented technical abstracts detailing the advantages of cryoenergy over radiofrequency-based (RF) treatments in reducing both thrombogenicity and the risk of coronary artery stenosis when treating cardiac arrhythmias.

These two animal studies from The Montreal Heart Institute and The University of Oklahoma Health Sciences Center, used Freezor technology from CryoCath Technologies, the world leader in cryotherapy products to treat cardiovascular disease, to generate their findings. The papers were presented at the American Heart Association conference in Anaheim, California, November 13, 2001.

"These papers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-12-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry